![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H12ClFN4 |
Molar mass | 326.76 g·mol−1 |
3D model (JSmol) | |
| |
|
Flualprazolam is a tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. It was first synthesised in 1976, [2] but was never marketed. It can be seen as the triazolo version of fludiazepam. It has subsequently been sold as a designer drug, [3] [4] [5] [6] first being definitively identified as such in Sweden in 2018. [7] [8] It can be described as the 2'-fluoro derivative of alprazolam or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects. [9] [10] [11] [12] [13]
Flualprazolam is banned in Sweden and illegal in the UK. [14] In December 2019, the World Health Organization recommended flualprazolam for international scheduling as a Schedule IV medication under the Convention on Psychotropic Substances. [15]
In the United States, Oregon and Virginia have placed Flualprazolam into Schedule I. [16] On December 23, 2022, the DEA announced it had begun consideration on the matter of placing Flualprazolam under temporary Schedule I status. [17] Later on July 25, 2023, the DEA published a pre-print notice that Flualprazolam would become temporarily scheduled as a Schedule I controlled substance from 26 July 2023 to 26 July 2025. [18] On July 25, 2025, and effective the following day, the DEA extended the temporary scheduling until July 26, 2026. [19]